Eric Palmer

Biography for Eric Palmer

Eric Palmer, Senior Editor

Eric Palmer is a business and technology journalist with more than three decades of prize-winning experience as a reporter and editor with daily, weekly, monthly and online publications. He was healthcare reporter for The Kansas City Star before becoming deputy business editor for the daily newspaper. He spent eight years as editor of The Kansas City Business Journal, which had a strong emphasis on the healthcare industry. On the personal side, he is an avid fly fisherman, cooks and collects wine, and likes to travel with his family. Eric is based in Kansas City and can be reached at [email protected].

Articles by Eric Palmer

Norwich Pharma spending $26M on new equipment

Contract manufacturer Norwich Pharma Services, which last year said it would be laying off about a fourth of its workforce, will now invest about $26 million in new equipment at its facility in Norwich, NY.

Sanofi Pasteur U.S. operation part of dengue vaccine buildup

Sanofi's highly anticipated dengue vaccine is being manufactured in a facility in France built specifically for the product. But expansion is also going on at Sanofi Pasteur's vaccine operation in Swiftwater, PA, in preparation for a launch of the vax which may happen later this year.

Catalent Kentucky expansion grows to $52M

CDMO Catalent started nearly two years ago on an expansion that it said would cost about $35 million and add about 80,000 square feet to its operation in Winchester, KY. But with additional investments in fluid bed capacity, the project ended up running to $52 million for an expansion of about 90,000 square feet, nearly double its original footprint.

Walgreens CEO hints at another supply chain deal

Walgreens Boots Alliance has been so pleased with its relationship with AmerisourceBergen that it might just look for another drug distributor with which to hook up. That was the suggestion made by Walgreens CEO Stefano Pessina this week.

Actavis asks court to let it stop manufacturing older Alzheimer's treatment

Actavis has made its case to a federal appeals court that it should be able to stop making the original version of its Alzheimer's treatment Namenda IR, which is going off patent, and replace it with its once-daily version Namenda XR.

Vectura will close plant in Germany within the year

U.K. respiratory drug specialist Vectura picked up a plant last year when it bought Germany's Activaero in a €130 million ($181 million) deal. But Vectura has decided it doesn't need it and will close the facility within a year in a cost-saving move.

Baxter again having to recall saline solution as shortage persists

Just weeks after recalling three lots of 0.9% sodium chloride injection amounting to nearly 600,000 units, Baxter has recalled 8 more lots, adding further to the national shortage of saline. Last time the problem was leaky bags. This time the drugmaker says there is a problem with the chance for particulate in the bags. The FDA also announced the recall in a MedWatch notice.

Novo opens $100M plant in Russia

A lot has changed in the Russian economy in the two years since Denmark's Novo Nordisk started work on its $100 million insulin plant there. But with the plant's opening Friday, Novo emphasized that it is taking the long view on a market that is much less promising than it was a few years ago.

Merck finds buyer for 2nd Puerto Rico plant slated to close

Merck put two of three plants in Puerto Rico on a hit list in 2013 as part of its efforts to cut costs and headcount. But after selling one last year to Sanofi's animal health unit Merial, it has found a buyer for the second, efforts that together will have saved about 400 jobs on the island.

Sanofi's vax plant in France preparing to produce 100M doses of dengue vaccine

Sanofi says it is "flipping the model" in its launch of the first approved vaccine to treat dengue. It will submit it for approval in dengue-stricken nations rather than first filing regulatory submissions in the U.S. and Europe.